Abstract
Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 37-46 |
| Number of pages | 10 |
| Journal | Keio Journal of Medicine |
| Volume | 60 |
| Issue number | 2 |
| Publication status | Published - 2011 Jun |
Fingerprint
Keywords
- Immunoglobulin
- Molecular target therapy
- Monoclonal antibody
ASJC Scopus subject areas
- Medicine(all)
Cite this
Therapeutic monoclonal antibodies. / Yamada, Taketo.
In: Keio Journal of Medicine, Vol. 60, No. 2, 06.2011, p. 37-46.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic monoclonal antibodies
AU - Yamada, Taketo
PY - 2011/6
Y1 - 2011/6
N2 - Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.
AB - Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs). In the 35 years since the first process for creating MoAbs was introduced, they have remained the centerpiece of the growing biotechnology and pharmaceutical industry. Herein, I review the history, development, and clinical settings of therapeutic MoAbs that have had a significant impact on life-saving medicine.
KW - Immunoglobulin
KW - Molecular target therapy
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=80051941878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051941878&partnerID=8YFLogxK
M3 - Article
VL - 60
SP - 37
EP - 46
JO - Keio Journal of Medicine
JF - Keio Journal of Medicine
SN - 0022-9717
IS - 2
ER -